ELCC 2016 | LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC

Kenneth O'Byrne

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Kenneth O’Byrne, MD, from Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Australia, discusses LUX-Lung 7, a phase 2b, global, randomized, open-label trial of afatinib compared with gefitinib as first-line treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter